Cadrenal Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Cadrenal Therapeutics, Inc. (CVKD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 285.00 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-03-31
- Cadrenal Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 5.00K shares.
- Cadrenal Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- Cadrenal Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Cadrenal Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 280.00K shares, a 72.55% decline year-over-year.
- Cadrenal Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 285.00K shares, a 265.38% increase from fiscal 2024.
- Cadrenal Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 78.00K shares, a 4.00% increase from fiscal 2023.
- Cadrenal Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 75.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | 5.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 5.00K shares derived: sum of 2 quarters · filed 2026-03-31 | 5.00K shares derived: sum of 3 quarters · filed 2026-03-31 | 285.00K shares 10-K · filed 2026-03-31 | ||
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 0.00 shares derived: sum of 2 quarters · filed 2025-11-10 | 280.00K shares 10-Q · filed 2025-11-10 | 280.00K shares derived: sum of 4 quarters · filed 2025-11-10 | ||
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 280.00K shares 10-Q · filed 2025-08-11 | 280.00K shares derived: sum of 3 quarters · filed 2025-08-11 | -812.00K shares derived: sum of 4 quarters · filed 2025-08-11 | ||
| 2025-03-31 | 280.00K shares 10-Q · filed 2025-05-08 | 280.00K shares derived: sum of 2 quarters · filed 2025-05-08 | -812.00K shares derived: sum of 3 quarters · filed 2025-05-08 | -662.00K shares derived: sum of 4 quarters · filed 2025-05-08 | ||
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -1.09M shares derived: sum of 2 quarters · filed 2025-03-13 | -942.00K shares derived: sum of 3 quarters · filed 2025-03-13 | 78.00K shares 10-K · filed 2025-03-13 | ||
| 2024-09-30 | -1.09M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -942.00K shares derived: sum of 2 quarters · filed 2024-11-07 | 78.00K shares 10-Q · filed 2024-11-07 | 78.00K shares derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2024-06-30 | 150.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 1.17M shares 10-Q · filed 2024-08-07 | 1.17M shares derived: sum of 3 quarters · filed 2024-08-07 | |||
| 2024-03-31 | 1.02M shares 10-Q · filed 2024-05-09 | 1.02M shares derived: sum of 2 quarters · filed 2024-05-09 | ||||
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | 75.00K shares 10-K · filed 2024-03-11 | ||||
| 2023-09-30 | 75.00K shares 10-Q · filed 2023-11-09 | |||||
| 2023-01-24 | 50.00K shares 10-Q · filed 2023-08-10 | |||||
| 2022-07-11 | 650.00K shares 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B |